TEVA: cercetata pentru practici de vanzari incorecte in legatura cu solutia injectabila Copaxone

TevaTeva este lider mondial in vanzarea de medicamente generice, iar aproximativ 20% din volumul vanzarilor este generat de Copaxone, solutie injectabila patentata pentru tratarea sclerozei multiple.

Reprezentantul Teva a declarat ca, in 8 ianuarie, i s-au solicitat companiei documente si informatii referitoare la Copaxone si un alt medicament, Azilect, din 2006 pana in prezent. Motivarea citatiei: posibile incalcari ale legii in promovarea medicamentelor (drug marketing).

Patentul Copaxone expira in luma mai, astfel ca Teva se asteapta ca medicamentele generice competitoare sa castige teren in a doua jumatate a anului, desi spera sa produca o varianta mai usor de utilizat a produsului, ca sa nu piarda pacientii.

TEVA under investigation over sales practices related to Copaxone

Teva is the world leader in sales of generic prescription medicine and an approximate 20% of its total revenue came in 2013 from sales of Copaxone, a patented injectable drug used to treat multiple sclerosis.

Teva said that on Jan. 8 it received a subpoena for documents and information related to Copaxone and another drug, Azilect, from 2006 to the present. Teva said the subpoena says the government is investigating possible “civil violations” of federal laws on drug marketing.

Copaxone’s main patents expire in May, so Teva expects generic competition to hurt sales in the second half of 2014, though it hopes an easier-to-use version will help it retain patients.

Surse: MED City News; imagine: wikipedia.org

Categorii: Industria farma si de sanatate, Stiri | Semn de carte | Urmareste comentariile | Comenteaza | Trackback URL |

Adauga un comentariu

Tu ce parere ai?
  1. *
  2. *
  3. *
  4. Captcha
 

cforms contact form by delicious:days